$NYMX No follow-through on Friday's bounce lol. But management beginning to re-engage with investors for the first time in over a year suggests there is a light at the end of the tunnel. I think they clearly have better visibility on filing, and we should hear about that within 5 weeks. Also I corresponded with another analyst who knows the company well. He maintains pricing will be at least $4k per dose (still less than Urolift,) thinks there's an 85% probability of approval, and also thinks applications are imminent. Glta longs, and I'm still adding on dips.
3
5
5 Likes